Neuroprotective effect of oleuropein following spinal cord injury in rats.

Lorestan University of Medical Sciences, Khorramabad, Iran.
Neurological Research (Impact Factor: 1.18). 01/2012; 34(1):44-51. DOI:10.1179/1743132811Y.0000000058
Source: PubMed

ABSTRACT Oleuropein (OE) is a well-known antioxidant polyphenol from olive oil. The purpose of this study was to determine the potential neuroprotective effects of oleuropein in an experimental spinal cord injury model.
Rats were randomly divided into four groups of 21 rats each as follows: sham-operated group, trauma group, and OE treatment groups (20 mg/kg, i.p., immediately and 1 hour after spinal cord injury). Spinal cord samples were taken 24 hours after injury and studied for determination of malondialdehyde and glutathione levels, histopathological assessment, immunohistochemistry of Bax and Bcl-2, and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling reaction. Behavioral testing was performed weekly up to 6 weeks post-injury.
The results showed that malondialdehyde levels were significantly decreased, and glutathione levels were significantly increased in OE treatment groups. Greater Bcl-2 and attenuated Bax expression could be detected in the OE-treated rats. OE significantly reduced terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling-positive reaction and improved behavioral function than the trauma group.
These findings indicate that OE may be effective in protecting rat spinal cord from secondary injury.

0 0
  • [show abstract] [hide abstract]
    ABSTRACT: Inflammation plays a central role in the pathogenesis of several brain disorders and neuronal injury, and it develops as a consequence of glial cell activation. Activated microglial cells generate potentially damaging nitric oxide, oxygen free radicals, prostanoids, and pro-inflammatory cytokines. Naturally occurring polyphenols have recently received attention for their potential protective effect on neurodegenerative disorders characterized by microglial activation, due to their anti-inflammatory and antioxidant properties. In the present study we investigated, using an in vitro model of primary microglia, the ability of 1-phenyl-6,7-dihydroxy-isochroman (encoded L 137), a natural polyphenolic compound, to inhibit microglia activation induced by an inflammatory insult. So, L137 effects (1-100μM) on production of pro-inflammatory mediators in lipopolisaccharide (LPS)-activated microglial cells were evaluated. The expression of inducible isoforms of nitric oxide synthase (iNOS) and cyclooxygenase (COX-2) as well as of the Nuclear transcription Factor-kappa B (NF-kB) was also performed in cellular lysates by Immunoblot. L137 significantly reduced Tumor Necrosis Factor (TNF)-α, interleukin (IL)-1β, IL-6 secretion, as well as nitric oxide (NO) and prostanoids [Thromboxane (TX)B2, Prostaglandin (PG)E2] production in activated microglial cells. Western blot analyses showed an inhibitory effect of L137 on the iNOS and COX-2 expression, mediated by a modulation of redox-sensitive nuclear transcriptional factor (NF)-kB, known to control a wide array of genes involved in inflammation. In conclusion, this study demonstrate that L137 is able to inhibit the production of pro-inflammatory and neurotoxic mediators by LPS-activated microglial cells thus suggesting L137 as a potential lead compound for drug development for neurodegenerative disorders where microglia-mediated inflammatory responses play an important pathogenic role.
    Brain research bulletin 04/2013; · 2.18 Impact Factor
  • 06/2013: pages 3605-3638;
  • [show abstract] [hide abstract]
    ABSTRACT: Among Spinal Cord Injury (SCI) intervention the administration of high-dose high-potency steroidal drugs such as methylprednisolone or dexamethasone is used to reduce the inflammation associated with primary injury and prevention of the subsequent secondary injury. The administration of steroids has several side-effects that jeopardize their use and therefore safer chemical neuro-entities are required. Natural compounds such as curcumin (anti-oxidant) and quercetin (anti-inflammatory) have been investigated as alternative neuroactive, but are not as potent as the steroids. Hence, they are required in very high doses which may lead to significant toxicity causing an increase in cellular levels of reactive oxygen species, active iron chelation, inhibiting the activity of the cytochrome P450 enzymes such as glutathione-S-transferase and UDP-glucuronosyltransferase. A reduction in the dose of these neuroactives is possible with the administration of a ‘chemically-variant’ permutation with additive or synergistic therapeutic benefits. Therefore, we hypothesize that curcumin and quercetin, both natural polyphenolic flavonoids, can “additively and synergistically” improve the physiological outcome after traumatic SCI when used in combination and termed ‘Cur(Que)min’ – thereby decreasing the dose levels and hence reducing the inherent high dose-cytotoxicity of the individual neuroactives. This hypothesis provides the first-account of a curcumin-quercetin combination for SCI intervention theorizing the possible biomolecular-mechanism that may provide the scientific community with a novel neuroprotective and neurotherapeutic treatment option for SCI.
    Medical Hypotheses 01/2014; · 1.05 Impact Factor


Available from
Jan 26, 2013